Restricted accessResearch articleFirst published online 2014-1
The Relationship between Platelet Collagen Receptor Glycoprotein VI and No-Reflow Phenomenon in Patients with Acute ST-Segment Elevation Myocardial Infarction
The purpose of this study was to determine whether admission soluble glycoprotein VI (sGP-VI) level is associated with no-reflow phenomenon (NRP) after primary percutaneous coronary intervention (P-PCI) in patients with acute ST-segment elevation myocardial infarction (STEMI).
Methods
A total of 178 consecutive patients admitted to our hospital for a first STEMI and undergoing P-PCI within 12 hours of onset of symptoms were enrolled. The patients were divided into 2 groups (NRP group and reflow group). Admission sGP-VI plasma levels were measured by enzyme-linked immunosorbent assay.
Results
Of the 178 patients who underwent P-PCI, 41 patients (23%) developed NRP. The patients in the reflow group had higher levels of sGP-VI compared with the patients in the NRP group (38.5 ± 21.0 vs 21.9 ± 11.9 ng/mL, P < 0.001). The sensitivity and specificity values of the sGP-VI levels were 90% and 49%, respectively (cutoff value was ≤25). In the multivariate logistic regression analyses, sGP-VI levels of 25 ng/mL or lower, higher peak troponin T levels and body mass index value, amount of opaque of greater than 250 mL, and lesion length of greater than 13.5 mm were independent predictors of angiographic NRP.
Conclusions
Lower admission sGP-VI levels are associated with NRP in patients with STEMI undergoing P-PCI. This outcome may open new therapeutic facility in the setting of P-PCI.
ZhangQ, ZhangRY, QiuJP, . Impact of different clinical pathways on outcomes of patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: the RAPID-AMI study. Chin Med J (Engl). 2009; 122: 636–642.
2.
ZhangQ, ZhangRY, QiuJP, . Prospective multicenter randomized trial comparing physician versus patient transfer for primary percutaneous coronary intervention in acute ST-segment elevation myocardial infarction. Chin Med J (Engl). 2008; 121: 485–491.
3.
MorishimaI, SoneT, MokunoS, . Clinical significance of no-reflow phenomenon observed on angiography after successful treatment of acute myocardial infarction with percutaneous transluminal coronary angioplasty. Am Heart J. 1995; 130: 239–243.
4.
GibsonCM, SchömigA. Coronary and myocardial angiography: angiographic assessment of both epicardial and myocardial perfusion. Circulation. 2004; 109: 3096–3105.
5.
KlonerRA, GanoteCE, JenningsRB. The “no-reflow” phenomenon after temporary coronary occlusion in the dog. J Clin Invest. 1974; 54: 1496–1508.
6.
KingSBIII, SmithSCJr, HirshfeldJWJr, . 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol. 2008; 51: 172–209.
7.
GibsonCM, CannonCP, MurphySA, . Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000; 101: 125–130.
8.
MorishimaI, SoneT, OkumuraK, . Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol. 2000; 36: 1202–1209.
9.
ReffelmannT, KlonerRA. The no-reflow phenomenon: a basic mechanism of myocardial ischemia and reperfusion. Basic Res Cardiol. 2006; 101: 359–372.
10.
ItoH. No-reflow phenomenon and prognosis in patients with acute myocardial infarction. Nat Clin Pract Cardiovasc Med. 2006; 3: 499–506.
11.
RezkallaSH, KlonerRA. Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory. Catheter Cardiovasc Interv. 2008; 72: 950–957.
HeindlB, ZahlerS, WelschU, . Disparate effects of adhesion and degranulation of platelets on myocardial and coronary function in postischaemic hearts. Cardiovasc Res. 1998; 38: 383–394.
15.
MassbergS, GawazM, GrünerS, . A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J Exp Med. 2003; 197: 41–49.
16.
NieswandtB, WatsonSP. Platelet-collagen interaction: is GPVI the central receptor?Blood. 2003; 102: 449–461.
17.
MoroiM, JungSM. Platelet glycoprotein VI: its structure and function. Thromb Res. 2004; 114: 221–233.
18.
WilnerGD, NosselHL, LeRoyEC. Aggregation of platelets by collagen. J Clin Invest. 1968; 47: 2616–2621.
19.
StephensG, YanY, Jandrot-PerrusM, . Platelet activation induces metalloproteinase-dependent GP VI cleavage to down-regulate platelet reactivity to collagen. Blood. 2005; 105: 186–191.
20.
BergmeierW, RabieT, StrehlA, . GPVI down-regulation in murine platelets through metalloproteinase-dependent shedding. Thromb Haemost. 2004; 91: 951–958.
21.
GardinerEE, ArthurJF, KahnML, . Regulation of platelet membrane levels of glycoprotein VI by a platelet-derived metalloproteinase. Blood. 2004; 104: 3611–3617.
22.
SchulzC, PenzS, HoffmannC, . Platelet GPVI binds to collagenous structures in the core region of human atheromatous plaque and is critical for atheroprogression in vivo. Basic Res Cardiol. 2008; 103: 356–367.
23.
BaumgartnerHR. Platelet interaction with collagen fibrils in flowing blood. I. Reaction of human platelets with alpha chymotrypsin-digested subendothelium. Thromb Haemost. 1977; 37: 1–16.
24.
HermillerJB, CusmaJT, SperoLA, . Quantitative and qualitative coronary angiographic analysis: review of methods, utility, and limitations. Cathet Cardiovasc Diagn. 1992; 25: 110–131.
25.
RentropKP, FeitF, ShermanW, . Serial angiographic assessment of coronary artery obstruction and collateral flow in acute myocardial infarction. Report from the second Mount Sinai-New York University Reperfusion Trial. Circulation. 1989; 80: 1166–1175.
26.
van ‘t HofAW, LiemA, SuryapranataH, . Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation. 1998; 97: 2302–2306.
27.
GibsonCM, de LemosJA, MurphySA., for the TIMI Study Group. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation. 2001; 103: 2550–2554.
28.
KillipTIII, KimballJT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol. 1967; 20: 457–464.
29.
PianaRN, PaikGY, MoscucciM, . Incidence and treatment of ‘no-reflow’ after percutaneous coronary intervention. Circulation. 1994; 89: 2514–2518.
30.
TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med. 1985; 312: 932–936.
31.
Al-TamimiM, MuFT, MoroiM, . Measuring soluble platelet glycoprotein VI in human plasma by ELISA. Platelets. 2009; 20: 143–149.
32.
ZijlstraF, de BoerMJ, HoorntjeJC, . A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med. 1993; 328: 680–684.
33.
WeaverWD, SimesRJ, BetriuA, . Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA. 1997; 278: 2093–2098.
34.
KeeleyEC, BouraJA, GrinesCL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003; 361: 13–20.
35.
ItoH, OkamuraA, IwakuraK, . Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation. 1996; 93: 1993–1999.
36.
ReffelmannT, KlonerRA. The “no-reflow” phenomenon: basic science and clinical correlates. Heart. 2002; 87: 162–168.
37.
CuraFA, L'AllierPL, KapadiaSR, ., for the RAPPORT Investigators. Predictors and prognosis of suboptimal coronary blood flow after primary coronary angioplasty in patients with acute myocardial infarction. Am J Cardiol. 2001; 88: 124–128.
38.
KaulS, ItoH. Microvasculature in acute myocardial ischemia: part II: evolving concepts in pathophysiology, diagnosis, and treatment. Circulation. 2004; 109: 310–315.
39.
IwakuraK, ItoH, IkushimaM, . Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol. 2003; 41: 1–7.
40.
TopolEJ, YadavJS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation. 2000; 101: 570–580.
KotaniJ, NantoS, MintzGS, . Plaque gruel of atheromatous coronary lesion may contribute to the no-reflow phenomenon in patients with acute coronary syndrome. Circulation. 2002; 106: 1672–1677.
43.
PratiF, PawlowskiT, GilR, . Stenting of culprit lesions in unstable angina leads to a marked reduction in plaque burden: a major role of plaque embolization? A serial intravascular ultrasound study. Circulation. 2003; 107: 2320–2325.
44.
MehranR, DangasG, MintzGS, . Atherosclerotic plaque burden and CK-MB enzyme elevation after coronary interventions: intravascular ultrasound study of 2256 patients. Circulation. 2000; 101: 604–610.
45.
ItoH, TomookaT, SakaiN, . Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation. 1992; 85: 1699–1705.
46.
ResnicFS, WainsteinM, LeeMK, . No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J. 2003; 145: 42–46.
47.
EeckhoutE, KernMJ. The coronary no-reflow phenomenon: a review of mechanisms and therapies. Eur Heart J. 2001; 22: 729–739.
KusamaI, HibiK, KosugeM, . Impact of plaque rupture on infarct size in ST-segment elevation anterior acute myocardial infarction. J Am Coll Cardiol. 2007; 50: 1230–1237.
51.
FrossardM, FuchsI, LeitnerJM, . Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation. 2004; 110: 1392–1397.
52.
PrzyklenkK, KlonerRA. “Reperfusion injury” by oxygen-derived free radicals? Effect of superoxide dismutase plus catalase, given at the time of reperfusion, on myocardial infarct size, contractile function, coronary microvasculature, and regional myocardial blood flow. Circ Res. 1989; 64: 86–96.
53.
GolinoP, MarokoPR, CarewTE. Efficacy of platelet depletion in counteracting the detrimental effect of acute hypercholesterolemia on infarct size and the no-reflow phenomenon in rabbits undergoing coronary artery occlusion-reperfusion. Circulation. 1987; 76: 173–180.
54.
HumphreySM, GavinJB, HerdsonPB. Catecholamine-depletion and the no-reflow phenomenon in anoxic and ischaemic rat hearts. J Mol Cell Cardiol. 1982; 14: 151–161.
55.
HumphreySM, SeelyeRN, GavinJB. The influence of adenosine on the no-reflow phenomenon in anoxic and ischaemic hearts. Pathology. 1982; 14: 129–133.
56.
WestinM, HedénP. Calcitonin gene-related peptide delays the no-reflow phenomenon in the rat island flap. Ann Plast Surg. 1988; 21: 329–334.
57.
RuggeriZM. Platelets in atherothrombosis. Nat Med. 2002; 8: 1227–1234.
CabezaN, LiZ, SchulzC, . Surface expression of collagen receptor Fc receptor-gamma/glycoprotein VI is enhanced on platelets in type 2 diabetes and mediates release of CD40 ligand and activation of endothelial cells. Diabetes. 2004; 53: 2117–2121.
60.
ChenH, LockeD, LiuY, . The platelet receptor GPVI mediates both adhesion and signaling responses to collagen in a receptor density-dependent fashion. J Biol Chem. 2002; 277: 3011–3019.
61.
BestD, SenisYA, JarvisGE, . GPVI levels in platelets: relationship to platelet function at high shear. Blood. 2003; 102: 2811–2818.
62.
SarrattKL, ChenH, ZutterMM, . GPVI and alpha2beta1 play independent critical roles during platelet adhesion and aggregate formation to collagen under flow. Blood. 2005; 106: 1268–1277.
63.
BigalkeB, LindemannS, EhlersR, . Expression of platelet collagen receptor glycoprotein VI is associated with acute coronary syndrome. Eur Heart J. 2006; 27: 2165–2169.
64.
PenzS, ReiningerAJ, BrandlR, . Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI. FASEB J. 2005; 19: 898–909.
65.
GardinerEE, ArthurJF, BerndtMC, . Role of calmodulin in platelet receptor function. Curr Med Chem Cardiovasc Hematol Agents. 2005; 3: 283–287.
66.
BoylanB, ChenH, RathoreV, . Anti–GPVI-associated ITP: an acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRgamma-chain complex from the human platelet surface. Blood. 2004; 104: 1350–1355.
67.
GardinerEE, KarunakaranD, ShenY, . Controlled shedding of platelet glycoprotein (GP)VI and GPIb-IX-V by ADAM family metalloproteinases. J Thromb Haemost. 2007; 5: 1530–1537.
68.
NieswandtB, SchulteV, BergmeierW, . Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. J Exp Med. 2001; 193: 459–469.
69.
MassbergS, KonradI, BültmannA, . Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J. 2004; 18 (2): 397–399.
70.
BültmannA, LiZ, WagnerS, . Impact of glycoprotein VI and platelet adhesion on atherosclerosis—a possible role of fibronectin. J Mol Cell Cardiol. 2010; 49: 532–542.
71.
ReiningerAJ, BernlochnerI, PenzSM, . A 2-step mechanism of arterial thrombus formation induced by human atherosclerotic plaques. J Am Coll Cardiol. 2010; 55: 1147–1158.
